Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)
Prevention & Treatment Protocols for COVID-19
Dr. Pierre Kory, MD.
Appearing as a witness on Dec. 8, 2020, before the Senate Committee on Homeland Security and Governmental Affairs—which held a hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution”— Dr. Pierre Kory, President of the Frontline COVID-19 Critical Care Alliance (FLCCC), called for the government to swiftly review the already expansive and still rapidly emerging medical evidence on ivermectin.
The data shows the ability of the drug ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover. Dr. Kory testified that ivermectin is effectively a “miracle drug” against COVID-19 and called upon the government’s medical authorities—the NIH, CDC, and FDA—to urgently review the latest data and then issue guidelines for physicians, nurse-practitioners, and physician assistants to prescribe ivermectin for COVID-19.
Mission Statement and Objectives of the FLCCC Alliance
Formed by leading critical care specialists in March 2020, at the beginning of the Coronavirus pandemic, the ‘Front Line COVID-19 Critical Care Alliance’ is now a 501(c)(3) non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve the outcomes for patients ill with the disease.
Since October 2020 we regard ivermectin as a core medication in the prophylaxis and treatment of COVID-19. The rationale for this can be found in our Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19.
Database of all ivermectin COVID-19 studies. 93 studies, 53 peer reviewed, 55 with results comparing treatment and control groups.